Summary
BeOne Medicines Ltd. (ONC) reported a strong third quarter of 2025, with total revenues reaching $1.41 billion, a significant 41% increase year-over-year. This growth was primarily driven by robust performance in product revenue, which rose 40.4% to $1.395 billion, led by a remarkable 50.8% surge in BRUKINSA® sales, now exceeding $1 billion globally for the quarter. The company also demonstrated improved profitability, swinging from a net loss in the prior year period to a net income of $124.8 million. This financial turnaround, coupled with an increase in R&D investment and SG&A expenses, reflects BeOne Medicines' strategic focus on expanding its commercial reach and advancing its promising oncology pipeline.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $1.41B |
| Gross Profit | $1.22B |
| R&D Expenses | $523.66M |
| SG&A Expenses | $529.00M |
| Operating Expenses | $1.05B |
| Operating Income | $163.11M |
| Interest Expense | $12.65M |
| Net Income | $124.84M |
| EPS (Basic) | $0.09 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.49B |
Key Highlights
- 1Total revenues increased by 41.0% to $1.41 billion for Q3 2025 compared to $1.00 billion in Q3 2024.
- 2Net product revenue grew by 40.4% to $1.395 billion for Q3 2025, primarily driven by BRUKINSA® sales.
- 3Global BRUKINSA® revenue reached $1.04 billion in Q3 2025, a 50.8% increase year-over-year.
- 4Income from operations turned positive, reaching $163.1 million in Q3 2025, a significant improvement from a loss of $120.3 million in Q3 2024.
- 5Net income was $124.8 million for Q3 2025, compared to a net loss of $121.4 million in Q3 2024.
- 6Diluted EPS (ADS) was $1.09 for Q3 2025, a substantial improvement from a loss of ($1.15) per ADS in Q3 2024.
- 7The company reported strong cash and cash equivalents, totaling $4.11 billion as of September 30, 2025, indicating a healthy liquidity position.